Crude incidence rates of fractures by medications in patients with rheumatoid arthritis
| No. with fracture/No. exposed | Patient-years | Incidence rates (95% CI)* | |
| All patients | 914/11 412 | 55 482 | 16.5 (15.4 to 17.6) |
| DMARD groups | |||
| Methotrexate monotherapy | 169/3213 | 9115 | 18.5 (15.9 to 21.6) |
| TNFi | 280/5150 | 18 561 | 15.1 (13.4 to 17.0) |
| Non-TNFi bDMARDs | 63/1420 | 3216 | 19.6 (15.3 to 25.1) |
| Other DMARDS | 402/7129 | 24 591 | 16.3 (14.8 to 18.0) |
| Glucocorticoid use | |||
| None | 547/8989 | 40 282 | 13.6 (12.5 to 14.8) |
| <7.5 mg/day for <3 months | 10/834 | 693 | 14.4 (7.8 to 26.8) |
| <7.5 mg/day for ≥3 months | 220/3387 | 10 149 | 21.7 (19.0 to 24.7) |
| ≥7.5 mg/day for <3 months | 15/809 | 660 | 22.7 (13.7 to 37.7) |
| ≥7.5 mg/day for ≥3 months | 121/1948 | 3616 | 33.5 (28.0 to 40.0) |
| Statins | 259/4187 | 15 412 | 16.8 (14.9 to 19.0) |
| Antidepressants | 236/3110 | 9536 | 25.1 (22.1 to 28.5) |
| SSRIs | 185/2369 | 6971 | 26.5 (23.0 to 30.6) |
| Others | 84/1339 | 3663 | 22.9 (18.5 to 28.4) |
| PPIs | 341/4963 | 16 820 | 20.3 (18.2 to 22.5) |
| Opioids | 388/5082 | 14 100 | 27.5 (24.9 to 30.4) |
| Weak opioids | 320/4566 | 12 244 | 26.1 (23.4 to 29.2) |
| Strong opioids | 116/1483 | 2885 | 40.3 (33.5 to 48.2) |
| NSAIDs | 412/7705 | 26 006 | 15.8 (14.4 to 17.4) |
| COX-2 inhibitors | 118/2945 | 7366 | 16.0 (13.8 to 19.2) |
| Non-selective NSAIDs | 300/6065 | 18 970 | 15.8 (14.1 to 17.7) |
| Anticonvulsants | 122/2072 | 5238 | 23.3 (19.5 to 27.8) |
| Antipsychotics | 35/643 | 1364 | 25.7 (18.4 to 35.7) |
| Benzodiazepines | 75/1223 | 2930 | 25.6 (20.4 to 32.1) |
*Per 1000 patient-years.
COX-2, cyclo-oxygenase-2; DMARD, disease-modifying antirheumatic drugs;NSAIDs, non-steroidal anti-inflammatory drugs;PPIs, proton pump inhibitors;SSRIs, selective serotonin reuptake inhibitors;TNFi, tumour necrosis factor-α inhibitor;bDMARDs, biological disease modifying antirheumatic drugs.